Business
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Company plans to resubmit BLA to the FDA in June 2026ISELIN, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the appeal following completion of the Formal Dispute Resolution (FDR) process with the Office of New Dr
About this update from Outlook Therapeutics, Inc.
[{"type":"image","alt":"Outlook Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Outlook Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":80,"url":"https://media.zenfs.com/en/globenewswire.com/036f630f46be050c02b981afef3ca9e4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ry.XC5VxIDK5aukGPfsBSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMg--/https://media.zenfs.com/en/globenewswire.com/036f630f46be050c02b981afef3ca9e4","width":300,"height":80},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ry.XC5VxIDK5aukGPfsBSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMg--/https://media.zenfs.com/en/globenewswire.com/036f630f46be050c02b981afef3ca9e4","width":300,"height":80}},"lazy":false},{"type":"text","content":"Company plans to resubmit BLA to the FDA in June 2026","length":53,"tagName":"p"},{"type":"text","content":"ISELIN, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the appeal following completion of the Formal Dispute Resolution (FDR) process with the Office of New Drugs (OND). The FDA concluded that substantial evidence of effectiveness has been established for LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD). As a result, Outlook Therapeutics expects to resubmit the ONS-5010/LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) in June 2026.","length":773,"tagName":"p"},{"type":"text","content":"The Company engaged in the FDR process after its recent Type A meeting with the Division of Ophthalmology (Division) and Office of Specialty Medicine (OSM) related to the December 30, 2025 Complete Response Letter (CRL) for the BLA for ONS-5010/LYTENAVA™.","length":255,"tagName":"p"},{"type":"text","content":"In its formal response, OND determined that the results of the NORSE TWO trial, together with confirmatory evidence including NORSE EIGHT, natural history, and mechanistic and pharmacodynamic data, establish substantial evidence of effectiveness for LYTENAVA™ for the treatment of nAMD. The response directs the Division and OSM to work with Outlook Therapeutics t...